- Home
- NRXP vs INKT Comparison
NRXP vs INKT Comparison
Compare NRXP & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- INKT
- Stock Information
- Founded
- NRXP 2015
- INKT 2017
- Country
- NRXP United States
- INKT United States
- Employees
- NRXP N/A
- INKT N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NRXP Health Care
- INKT Health Care
- Exchange
- NRXP Nasdaq
- INKT Nasdaq
- Market Cap
- NRXP 32.6M
- INKT 28.8M
- IPO Year
- NRXP N/A
- INKT 2021
- Fundamental
- Price
- NRXP $3.02
- INKT $21.19
- Analyst Decision
- NRXP Strong Buy
- INKT Hold
- Analyst Count
- NRXP 4
- INKT 3
- Target Price
- NRXP $28.50
- INKT $37.50
- AVG Volume (30 Days)
- NRXP 187.5K
- INKT 2.9M
- Earning Date
- NRXP 08-13-2025
- INKT 08-12-2025
- Dividend Yield
- NRXP N/A
- INKT N/A
- EPS Growth
- NRXP N/A
- INKT N/A
- EPS
- NRXP N/A
- INKT N/A
- Revenue
- NRXP N/A
- INKT N/A
- Revenue This Year
- NRXP N/A
- INKT N/A
- Revenue Next Year
- NRXP N/A
- INKT N/A
- P/E Ratio
- NRXP N/A
- INKT N/A
- Revenue Growth
- NRXP N/A
- INKT N/A
- 52 Week Low
- NRXP $1.10
- INKT $4.56
- 52 Week High
- NRXP $6.01
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- NRXP 43.71
- INKT 52.86
- Support Level
- NRXP $2.89
- INKT $18.67
- Resistance Level
- NRXP $3.53
- INKT $76.00
- Average True Range (ATR)
- NRXP 0.15
- INKT 7.71
- MACD
- NRXP -0.06
- INKT -0.03
- Stochastic Oscillator
- NRXP 18.97
- INKT 19.20
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.